A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosis.

Area of Science:

• Immunology
• Neuroscience
• Microbiome Research

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease impacting the central nervous system.
• The gut microbiome's role in MS is known, but specific mechanisms remain unclear.
• Understanding microbial influence is crucial for developing effective MS therapies.

Purpose of the Study:

• To investigate the role of microbial metabolites in multiple sclerosis pathogenesis.
• To explore the link between gut microbiome-derived compounds and immune system regulation in MS.
• To identify potential therapeutic targets for autoimmune diseases based on microbial metabolites.

Main Methods:

• Serum levels of indole-3-carboxaldehyde (3-IAld) were measured in multiple sclerosis patients.
• The interaction of 3-IAld with the Aryl hydrocarbon Receptor (AhR) was analyzed.
• Mast cell tryptophan metabolism and serotonin production were assessed in response to 3-IAld.

Main Results:

• Serum 3-IAld levels inversely correlated with multiple sclerosis disease duration.
• 3-IAld activated the Aryl hydrocarbon Receptor (AhR), similar to L-Kynurenine.
• Microbial 3-IAld modulated mast cell tryptophan metabolism, inducing serotonin production via Tph1.

Conclusions:

• Microbiome-derived 3-IAld may exert a protective effect in multiple sclerosis through AhR-mast cell activation.
• Microbial metabolites play a physiological role in immune homeostasis.
• AhR activation by microbial postbiotics represents a potential therapeutic strategy for autoimmune diseases.